BOSTON --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) and Prism Health Care Services, Inc. , an affiliate of The Alden Network, today announced an agreement under which Prism will be the exclusive distributor of Quell ® wearable pain relief technology in Illinois and Wisconsin for patients in

WALTHAM, Mass. , Nov. 15, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), announced today that it had executed a distribution agreement with Fukuda Denshi Co. Ltd. for DPNCheck ® , the Company’s  rapid, point-of-care test for diabetic peripheral neuropathy (DPN).

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported an agreement with Fukuda Denshi for DPNCheck ® distribution in Japan . DPNCheck is NeuroMetrix' rapid, accurate, and quantitative point-of-care test to detect diabetic peripheral neuropathy.

To be Available in March 2016 WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it received a 510(k) clearance (K152954) from the U.S. Food and Drug Administration (FDA) for an upgraded version of Quell, the company's over-the-counter, 100% drug free chronic

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported that it has started shipping Quell wearable pain relief devices out of its production and fulfillment facility in Woburn, MA. The initial shipments are directed to leading doctors and thought leaders in chronic pain.

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced that Frank McGillin , Senior Vice President and General Manger , Consumer, will participate in a panel discussion on the THE DIGITAL HEALTHCARE REVOLUTION at the Wearable Technology Show in Santa Clara, CA on

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced that Frank McGillin , Senior Vice President and General Manager, Consumer will participate in a panel discussion entitled "The Rise of Enterprise & Condition-Specific Wearables" during the Fifth Annual Digital Health

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) announced a high level of interest in Quell, the company's over-the-counter, 100% drug free chronic pain relief wearable at CES 2016. Highlights of the Week include: Quell was selected as one of 10 finalists in the CES Last Gadget

NeuroMetrix Announces Initial Commercial Shipment of SENSUS™ Pain Management System WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 7, 2013-- NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com , a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes,

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,173,581. The patent covers the core technology deployed in the DPNCheck device. The claims cover the novel integrated design of the hand-held